Search

Program

Saturday, June 15, 2024 - Presidential Session I

Conducting multinational RCTs in pregnancy to improve maternal health in thrombosis: it CAN be done   

Prof.  Saskia Middeldorp, The Netherlands

Targeting the epigenome in lymphoma 

Prof.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

Read more

EHA-SWG Scientific Meeting on Pediatric Hematology 2022

On April 7-9, 2022 the EHA-SWG Scientific Meeting on Pediatric Hematology was successfully held at the NH Collection Vittorio Veneto hotel in Rome.

Read more

Dr A van Hylckama Vlieg Announced Winner of the first EHA-ISTH Joint Fellowship

The award of EUR 72,000 over two years is intended to support the study of the physiology of bleeding, coagulation or thrombosis. Dr.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

EHA joins ESMO in calling for EU action on shortages of essential medicines

EHA joins ESMO in calling for EU action on shortages of essential medicines

The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more